Clinical trial · Observational
Study of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Participants With Early/Metastatic Breast Cancer in Saudi Arabia
A Retrospective, Observational Molecular Epidemiology Study of HER2 Expression in Patients With Early / Metastatic Breast Cancer in Saudi Arabia
NCT02954471CI-TRIAL-00040749completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a retrospective, multicenter study, consisting of chart review of Saudi Arabian participants diagnosed with breast cancer between 2007 and 2013 and with available human epidermal growth factor receptor 2 (HER2) testing. Data on survival will be collected through 2015.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Participants With Breast Cancer
- description
- This study will retrospectively collect data from participants with breast cancer in Saudi Arabia.
Primary outcomes (1)
- measure
- Percentage of Participants With Positive HER2 Test Result
- timeFrame
- From January 2007 to December 2013 (Up to 7 years; assessed retrospectively)
Secondary outcomes (9)
- measure
- Percentage of Participants With Estrogen Receptor/Progesterone Receptor Positive Breast Cancer
- timeFrame
- From January 2007 to December 2013 (Up to 7 years; assessed retrospectively)
- measure
- Percentage of Participants by Type of First-line and Subsequent Treatment Regimens Used
- timeFrame
- From January 2007 to December 2013 (Up to 7 years; assessed retrospectively)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Initially diagnosed with breast cancer * Has a proven result of HER2 testing by immunohistochemistry (IHC), fluorescent in situ hybridization (FISH) or any other in situ hybridization (ISH) method * Alive or not alive Exclusion Criteria: \- Inconclusive, equivocal or unavailable result of HER2/neu overexpression by IHC and FISH
References
Publications (0)
Data not yet available
No reference posted for this study.